Concepts (59)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Authorship | 1 | 2020 | 288 | 0.550 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2022 | 616 | 0.530 |
Why?
|
| Rectum | 1 | 2020 | 896 | 0.490 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2022 | 961 | 0.460 |
Why?
|
| Physicians, Women | 1 | 2020 | 512 | 0.440 |
Why?
|
| General Surgery | 3 | 2020 | 1722 | 0.400 |
Why?
|
| Rectal Neoplasms | 1 | 2020 | 1182 | 0.370 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 2895 | 0.310 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 6364 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 9373 | 0.190 |
Why?
|
| Cost Savings | 1 | 2020 | 904 | 0.120 |
Why?
|
| Sex Distribution | 1 | 2020 | 2263 | 0.120 |
Why?
|
| Tumor Burden | 1 | 2020 | 1885 | 0.110 |
Why?
|
| Azides | 1 | 2013 | 120 | 0.110 |
Why?
|
| Aminoacyltransferases | 1 | 2013 | 52 | 0.110 |
Why?
|
| Patient Preference | 1 | 2019 | 952 | 0.090 |
Why?
|
| Cysteine Endopeptidases | 1 | 2013 | 542 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2022 | 8529 | 0.090 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 6832 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 6499 | 0.080 |
Why?
|
| Internship and Residency | 2 | 2020 | 5946 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 1 | 2019 | 1806 | 0.080 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 1941 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2019 | 2172 | 0.080 |
Why?
|
| Laparoscopy | 1 | 2020 | 2039 | 0.080 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2019 | 1416 | 0.080 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2019 | 1379 | 0.080 |
Why?
|
| Green Fluorescent Proteins | 1 | 2013 | 2060 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 5526 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 11206 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2020 | 81514 | 0.050 |
Why?
|
| Receptor, erbB-2 | 1 | 2013 | 2593 | 0.050 |
Why?
|
| Nanoparticles | 1 | 2013 | 1964 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 2013 | 3837 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 36532 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 26318 | 0.040 |
Why?
|
| Maryland | 1 | 2019 | 278 | 0.040 |
Why?
|
| United States | 3 | 2020 | 72903 | 0.040 |
Why?
|
| Specialty Boards | 1 | 2019 | 234 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2020 | 54802 | 0.030 |
Why?
|
| Humans | 6 | 2022 | 765968 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 59489 | 0.030 |
Why?
|
| Male | 3 | 2020 | 363698 | 0.030 |
Why?
|
| Click Chemistry | 1 | 2013 | 100 | 0.030 |
Why?
|
| Focus Groups | 1 | 2019 | 1459 | 0.030 |
Why?
|
| Female | 3 | 2020 | 396112 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2019 | 1260 | 0.020 |
Why?
|
| Fluorescence | 1 | 2013 | 753 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2019 | 2354 | 0.020 |
Why?
|
| Aged | 2 | 2020 | 171117 | 0.020 |
Why?
|
| Middle Aged | 2 | 2020 | 223009 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 2418 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 5020 | 0.020 |
Why?
|
| Adult | 1 | 2020 | 223044 | 0.020 |
Why?
|
| Decision Making | 1 | 2019 | 3965 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2019 | 4863 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2013 | 5125 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 81819 | 0.000 |
Why?
|
| Animals | 1 | 2013 | 168764 | 0.000 |
Why?
|
Concepts
(59)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(2)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_